E-News Newsletter - July 2022
American Society of Clinical Oncology

RECAP: Alliance NCTN/NCORP/AFT at 2022 ASCO

Alliance investigators presented more than 20 abstracts, sharing the latest findings on breast cancer, lung cancer, GI and GU cancers, along with cancer control research at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 3-7 in Chicago. The annual meeting brought together thousands of oncology professionals from around the world under the theme: "Advancing Equitable Cancer Care Through Innovation." Highlighted were studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship. 
 
Here's a snapshot of studies that Alliance researchers presented:

Breast Cancer—Local/Regional/Adjuvant
CALGB 9741
Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance)
First Author: Otto Metzger, MD
Oral Abstract Session

CALGB 40601
Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials
Presenter: Aranzazu Fernandez-Martinez, MD, PhD
Poster Session

AFT-05
Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial
Presenter: Georg Pfeiler, MD
Poster Session

AFT-55
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)
Presenter: Thomas Meyskens
Poster Session

Central Nervous System Tumors
Alliance A071102
Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102)
First Author: Jann N. Sarkaria, MD
Oral Abstract Session

Gastrointestinal Cancer—Colorectal and Anal
A152108, CALGB 80405
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC)
Presenter: Hiroyuki Arai, MD, PhD

CALGB 80405
Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance)
First Author: Christine G. Kohn, PharmD, MD
Poster Session

Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405
First Author: Wu Zhang, MD
Poster Session

NCCTG N0147
Effect of primary tumor sidedness on the association of tumor-infiltrating lymphocytes with survival of patients with stage III colon cancer (NCCTG N0147) [alliance]
First Author: Bahar S. Ardestani, MD, MPH
Poster Session

Genitourinary Cancer—Kidney and Bladder
Alliance A032001
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)
First Author: Shilpa Gupta, MD
Poster Session

CALGB 90601
Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance)
First Author: Gopa Iyer, MD
Poster Session

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P)
First Author: David J. McConkey, PhD
Poster Session

Alliance A031701
A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)
First Author: Gopa Iyer, MD
Poster Session

Genitourinary Cancer—Prostate, Testicular, and Penile
Alliance A031902
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)
First Author: Arpit Rao, MD
Poster Session

Health Services Research and Quality Improvement
Alliance A152031
Analysis of patient (pt) withdrawal of consent using 11,993 pts from 58 alliance for clinical trials in oncology trials
First Author: Sumithra J. Mandrekar, PhD
Poster Session

Alliance A231602CD
Self-reported financial difficulties among patients with multiple myeloma and chronic lymphocytic leukemia: An Alliance for Clinical Trials in Oncology study
First Author: Rena M. Conti, PhD
Poster Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Alliance A051902
Alliance A051902: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas
First Author: Neha Mehta-Shah, MD
Poster Session

Hematologic Malignancies—Plasma Cell Dyscrasia
AFT-29
Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN
Presenter: Cesar Rodriguez MD
Poster Session

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Alliance A092001
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001)
First Author: Aaron S. Mansfield, MD
Poster Session

CALGB 70702
Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702)
First Author: Apar K. Ganti, MD
Oral Abstract Session

Symptoms and Survivorship
Alliance A152124
Deficit Accumulation Frailty Index (DAFI) scores and acute myeloid leukemia outcomes
Presenter: Catherine Lai, MD, MPH

Alliance A221602
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (Alliance A221602)
First Author: Rudolph M. Navari, PhD, MD
Poster Session